Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of intravenous zoledronic acid on bone metabolism in cancer patients with bone metastases
2005-002132-94Phase 4Completed
- Sponsor
- Novartis
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zoledronic acid in prostate cancer (PCa), breast cancer and bone metastases, sponsored by Novartis. Primary endpoints: Change in bone turnover markers over 4 months and Relationship between bone turnover markers and tumor burden. Started Nov 2005; status: completed.
02
Drugs
zoledronic acid
03
Conditions
prostate cancer (PCa)breast cancerbone metastases
Beyond the preview
Go deeper on 2005-002132-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002132-94.